Trial profile John A Dormandy et al. Lancet 2005;366:1279-89

Baseline characteristics John A Dormandy et al. Lancet 2005;366:1279-89

Macrovascular morbidity at study entry and associated medications John A Dormandy et al. Lancet 2005;366:1279-89

Kaplan-Meier curve of time to primary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

Kaplan-Meier curve of time to main secondary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

Numbers of first events contributing to the primary composite and main secondary endpoints John A Dormandy et al. Lancet 2005;366:1279-89

Effect of pioglitazone and placebo on each component of the primary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

Hazard associated with relevant baseline characteristics for the main secondary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

Change in proportion of patients using concomitant medications John A Dormandy et al. Lancet 2005;366:1279-89

Kaplan-Meier curve of time to permanent insulin use John A Dormandy et al. Lancet 2005;366:1279-89

Change in laboratory data from baseline to final visit John A Dormandy et al. Lancet 2005;366:1279-89

Serious adverse event summary John A Dormandy et al. Lancet 2005;366:1279-89

Reports of heart failure John A Dormandy et al. Lancet 2005;366:1279-89